Imbrium Therapeutics Pipeline
Our robust and diversified pipeline of investigational therapy candidates has been built to address many serious medical conditions.
Tinostamustine is a first-in-class, new chemical entity that combines two potentially synergistic mechanisms modes of action, alkylating activity and pan histone deacetylase inhibition (or HDAC inhibition). In early clinical studies, Tinostamustine has shown promising efficacy in patients who have exhausted treatment options (relapsed/refractory malignancies).
Sunobinop is a first-in-class, new chemical entity that potently and selectively activates nociceptin/orphanin-FQ (NOP) receptors. In clinical studies, Sunobinop has shown dose-dependent, statistically significant and clinically meaningful enhancement of sleep and is also under investigation for interstitial cystitis pain and overactive bladder.
KL-01401 is a novel film formulation for the emergency treatment of Anaphylaxis Associated with Severe Allergic Reactions. KL-01401 has the potential to be a substantial improvement over existing treatments including epinephrine injection.
IMB-150 is a novel inflammation targeting formulation of a non-opioid treatment for interstitial cystitis/bladder pain syndrome. Preclinical data has demonstrated favorable pharmacokinetics for IMB-150 with a prolonged duration of action.
1IAAC = Insomnia Associated with Alcohol Cessation
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the investigational agents will successfully complete clinical development or gain approval from the United States Food and Drug Administration or other health authorities.